BioAge Labs (NASDAQ:BIOA) Posts Quarterly Earnings Results

BioAge Labs (NASDAQ:BIOA) released its quarterly earnings data on Tuesday. The company reported ($0.72) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $3.08 million for the quarter.

BioAge Labs Trading Down 1.2%

BioAge Labs stock opened at $18.41 on Tuesday. The firm has a market capitalization of $660.07 million, a price-to-earnings ratio of -12.20 and a beta of 1.21. The firm has a 50 day simple moving average of $20.29 and a 200 day simple moving average of $12.76. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $24.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BIOA shares. Morgan Stanley set a $23.00 target price on shares of BioAge Labs in a report on Wednesday, February 4th. Citigroup boosted their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Oppenheimer started coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.00.

Insider Activity

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kristen Fortney sold 233,107 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the sale, the chief executive officer owned 976,949 shares in the company, valued at approximately $17,702,315.88. This represents a 19.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 267,540 shares of company stock worth $4,895,168. 20.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioAge Labs

Large investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of BioAge Labs during the third quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of BioAge Labs in the 4th quarter worth approximately $77,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs in the 2nd quarter worth approximately $27,000. Finally, Nisa Investment Advisors LLC raised its stake in BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.